title: Dual effects of ATP on isolated arteries of the bovine eye.
abstract: Although the presence of purinoreceptors has been shown in many human and animal arteries, there is few data yet about their role in the arteries of the eye. The purpose of the present study was to evaluate the effects of several agonists of purinoreceptors on isolated arteries of the bovine eye. Responses of isolated preparations of bovine ophthalmic (OA) and posterior ciliary arteries (PCA) to agonists of purinoreceptors (ATP, α,β-methylene-ATP-α,β-meATP, 2-methylthioATP-2meSATP, uridine-5'-triphosphate-UTP) as well as agonists of adreno-, cholino-, adenosine and histamine receptors were recorded by a standard organ bath method. ATP induced contractions of the intact vessels but caused relaxation of α,β-meATP-pretreated arteries. Contractile responses of PCA to high concentrations of ATP and α,β-meATP were significantly stronger than responses of OA, as well as relaxative responses to ATP and adenosine were significantly stronger in PCA than in OA. We suggest that there are several subtypes of functionally active purinoreceptors in both OA and PCA, although the potency of agonists of purinoreceptors to produce mechanical responses is higher in PCA than in OA. Purinoreceptors can be potential targets for new drugs, treating vascular pathology of the eye.
authors.affiliation: Kazan State Medical University, 49 Butlerov Str., Kazan 420012, Russia.
authors.forename: Anna P
authors.initials: AP
authors.lastname: Ziganshina
authors.forename: Bulat A
authors.initials: BA
authors.lastname: Ziganshin
authors.forename: Ayrat U
authors.initials: AU
authors.lastname: Ziganshin
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002417:Cattle; D019842:Ciliary Arteries / Q000187:drug effects* / Q000502:physiology; D005123:Eye / Q000098:blood supply / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology; D066298:In Vitro Techniques; D009638:Norepinephrine / Q000494:pharmacology; D009799:Ocular Physiological Phenomena / Q000187:drug effects; D009880:Ophthalmic Artery / Q000187:drug effects* / Q000502:physiology; D058906:Purinergic P1 Receptor Agonists / Q000494:pharmacology*; D058910:Purinergic P2 Receptor Agonists / Q000494:pharmacology*; D017981:Receptors, Neurotransmitter / Q000502:physiology*; D013873:Thionucleotides / Q000494:pharmacology; D014544:Uridine Triphosphate / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
chemical_list: D058906:Purinergic P1 Receptor Agonists; D058910:Purinergic P2 Receptor Agonists; D017981:Receptors, Neurotransmitter; D013873:Thionucleotides; D006632:Histamine; D000255:Adenosine Triphosphate; D002217:Carbachol; D000241:Adenosine; C002630:alpha,beta-methyleneadenosine 5'-triphosphate; D014544:Uridine Triphosphate; D009638:Norepinephrine; C008501:2-methylthio-ATP